

- treatment of
 in absent or nonbulky mediastinal lymph node disease, 518–519
 biologic therapy, 520, 521
 chemotherapy, 517–519, 518t, 522
 EGFR inhibitors, 521, 521t
 gene therapy, 91e-4
 maintenance chemotherapy, 520–521, 520t
 in mediastinal lymph node disease, 519
 in metastatic disease, 519–520, 520t
 neoadjuvant chemotherapy, 518
 in Pancoast tumors, 519
 prophylactic cranial irradiation, 522
 radiation therapy, 517, 522
 supportive care, 521
 surgical resection, 514, 516–517, 522
 targeted chemotherapy, 102e-3, 102e-5t, 102e-16, 102e-19, 103e-17t, 521
 tumor markers in, 473t
- Lung disease. *See also* Respiratory disorders; *specific disorders*
 air pollution and, 1693
 barotrauma-related, 477e-7
 biomass smoke-induced, 1693–1694, 1694f
 cancer. *See* Lung cancer
 cyanosis in, 249
 in cystic fibrosis, 1697. *See also* Cystic fibrosis (CF)
 deaths from, 56t
 global considerations in, 1693–1694
 high-altitude travel and, 476e-5
 IgG4-related, 391e-1t
 indoor exposures and, 1693
 infections in cancer patient, 488–489, 489t
 as late consequences of cancer/cancer therapy, 621–622
 in leptospirosis, 1143f
 obesity and, 415e-6
 occupational. *See* Occupational illness, lung disease
 pulmonary hypertension in, 1658
 respiratory acidosis in, 323
 in rheumatoid arthritis, 2138
 in sarcoidosis, 2206–2207, 2206f, 2206t
 in SLE, 1714, 2129, 2129t
 in systemic sclerosis, 2157–2158, 2158f, 2160–2161, 2161f
 in tularemia, 1068
- Lung flukes (*Paragonimus* spp.)
 clinical features of, 1429
 diagnosis of, 245e-2t, 245e-5t
 eosinophilia caused by, 765t
 epidemiology of, 245, 245e-2t, 765t, 1423t, 1429
 hemoptysis caused by, 245
 life-cycle hosts of, 245e-2t
 treatment of, 246e-13, 1428t, 1429
- Lung injury, acute. *See* Acute lung injury
- Lung lavage, 263e-7
- Lung stem cells, 453, 453t
- Lung transplantation
 complications of, 320e-3–4, 320e-3t
 for COPD, 1706
 cost of, 320e-3
 for cystic fibrosis, 320e-1t, 320e-2, 1699
 indications for, 320e-1
 infections in recipient, 924t, 926–927
 MRA of anastomosis following, 1667f
 organ allocation for, 320e-1–2
 outcomes of, 320e-2–3, 320e-2t
 post-transplantation management, 320e-2, 2764t
 procedure, 320e-2
 for pulmonary lymphangiomyomatosis, 1715
 recipient selection, 320e-1, 320e-1t
- Lung volume(s), 306e-1–2, 306e-2f, 306e-6
- Lung volume reduction surgery, 1706
- Lungworm, rat. *See* *Angiostrongylus* spp. infections
- Lupus anticoagulants
 in antiphospholipid syndrome, 2134
 laboratory evaluation of, 406, 2135t
 in SLE, 2131
- in thrombotic disease, 740
 warfarin therapy and, 756
- Lupus erythematosus
 acute cutaneous, 375, 375f
 discoid (chronic cutaneous). *See* Discoid (chronic cutaneous) lupus erythematosus
 drug-induced, 40, 44, 2218t
 subacute, 25e-3f, 2128
 subacute cutaneous, 356, 356t, 364t, 366, 367, 375, 2218t
 systemic. *See* Systemic lupus erythematosus (SLE)
- Lupus hairs, 354
- Lupus nephritis
 classification of, 1838, 1838t, 2126, 2127t
 clinical features of, 1838, 1858, 2128, 2129t
 crescentic, 2133
 membranous, 2133
 pathogenesis of, 1833, 1838
 renal biopsy in, 62e-5f, 1838
 treatment of, 1838–1839, 2128, 2130t, 2133
- Lupus pernio, 364t, 367, 2207, 2207f
- Lupus profundus, 2128
- Lupus vulgaris, 364t, 367
- Lurasidone, 2718, 2722t
- Lusitropic effect, 265e-7f
- Lutein, 96e-7
- Luteinizing hormone (LH), **401e-4**
 action of, 400e-2, 401e-4, 2377
 deficiency of, 2259t
 ectopic production of, 609t
 expression and regulation of, 401e-1t, 401e-2f
 feedback control of, 400e-6
 in females, age-related changes in levels of, 2376–2377, 2377f
 laboratory evaluation of, 2258t
 in male pubertal development, 2358
 in menstrual cycle regulation, 2378–2379, 2379f
 in ovarian follicle development, 2375f, 2376
 in perimenopause, 2381, 2381f
 pNET secreting, 559t, 571
 reference values for, 2761t
 secretion of, 401e-4, 2376
 synthesis of, 401e-4
- Luteinizing hormone (LH) receptor, 437, 2252
- Luteinizing hormone–releasing hormone (LHRH) agonists, 103e-15
- ¹⁷⁷Lutetium, 575
- LUTS (lower urinary tract symptoms), 7e-4, 587, 587t
- LVADs. *See* Left ventricular assist devices (LVADs)
- LVR (Laparoscopic Ventral Rectopexy), for rectal prolapse, 1974, 1975f
- Lycopene, 96e-7
- Lying to patient, 17e-1
- Lyme borreliosis (Lyme disease), **1149**
 chronic, 1151, 1153
 climate change and, 151e-5–6, 151e-6f
 clinical features of, 129t, 356, 1150–1151
 arthritis, 372e-24t, 835–836
 AV conduction block, 278e-4f, 1151, 1471t, 1472
 chronic meningitis, 907t
 disseminated infection, 1150–1151
 erythema migrans, 25e-2f, 129t, 134, 355–356, 1150, 1150f
 evolution of, 129t, 134, 356, 1150
 facial palsy, 2648
 localized infection, 1150
 myocarditis, 1561
 myositis, 2198
 neuropathy, 2633, 2684
 persistent infection, 1151
 SA node dysfunction, 1467t
 co-infection with *Babesia*, 1152, 1385, 1386
 diagnosis of, 770, 1151–1152, 1152t
 differential diagnosis of, 134, 1152
 epidemiology of, 1149
 etiology of, 1149
 pathogenesis of, 1150
 prevention of, 1153, 2745
- prognosis for, 1153
 prophylaxis for, 1153, 2745
 regional variations in, 1151
 reinfection in, 1153
 ticks in, 1149, 2745
 treatment of, 836, 1152–1153, 1152t, 1153f
- Lymphadenitis, tuberculous, 1109, 1109f
- Lymphadenopathy, **407**
 approach to the patient, 407–409
 benign, 407
 diseases associated with, 408t
 in fever of unknown origin, 141
 IgG4-related, 391e-1t, 391e-3
 infections associated with, 408, 408t, 763–764
Brucella, 194e-3
 cat-scratch disease, 1079, 1080f
 HIV infection, 1232–1233, 1262. *See also* HIV infection
 nontuberculous mycobacteria, 1130
 plague, 1072, 1072f
 tularemia, 1068, 1068f
 laboratory evaluation of, 409
 localized/regional, 408
 in Sjögren's syndrome, 2167, 2167t
 with splenomegaly, 408
 thoracic/abdominal, 408–409
- Lymphangiectasia, intestinal. *See* Intestinal lymphangiectasia
- Lymphangiography, 1654
- Lymphangiomyomatosis, pulmonary, 308e-5f, 1714–1715
- Lymphangitis, 968, 1654
- Lymphatic filariasis, **1417**
 clinical features of, 152e-6t, 837, 1417–1418, 1418f, 1419f, 1654
 diagnosis of, 152e-6t, 245e-3t, 245e-6, 245e-6t, 1418–1419
 differential diagnosis of, 1419
 epidemiology of, 1417, 1418t
 incubation period for, 152e-6t
 pathogenesis of, 1417
 prevention and control of, 1420
 in returning war veterans, 152e-6t
 treatment of, 152e-6t, 246e-8, 837, 1419–1420
- Lymphatic obstruction, 253, 269
- Lymphedema, **1653**
 anatomic considerations in, 1653
 clinical features of, 1654, 1654f
 congenital, 1653
 diagnosis of, 1654–1655
 differential diagnosis of, 1654
 etiology of, 1653–1654, 1653t
 in lymphatic filariasis, 1418, 1418f, 1419f, 1654
 pathophysiology of, 253
 stages of, 1654t
 treatment of, 1655
- Lymphedema praecox (Meigs's disease), 594, 1653–1654, 2620
- Lymphedema tarda, 1650
- Lymph node biopsy, 409
- Lymphocyte(s)
 B. *See* B cell(s)
 endothelial cell interactions of, 372e-26–28, 372e-28f, 372e-29t
 large granular, 81e-2, 372e-1, 372e-6
 in peripheral blood smear, 81e-2
 reactive, 81e-2
 T. *See* T cell(s)
- Lymphocytic choriomeningitis (LCM), 891, 893, 908t, 1306t, 1317–1318
- Lymphocytic colitis, 1957
- Lymphocytic gastritis, 1931
- Lymphocytic hypophysitis, 2257
- Lymphocytic interstitial pneumonitis, 1716
- Lymphocytic meningitis, 909t
- Lymphocytic variant hypereosinophilia, 135e-7, 135e-7t
- Lymphocytoma cutis, 364t, 367
- Lymphogranuloma venereum (LGV)
 clinical features of, 880f, 880t, 1169–1170, 1654
 complications of, 1170
 diagnosis of, 1170t
 epidemiology of, 879, 1169
 lymphadenopathy in, 408